Cargando…
Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
BACKGROUND: Low-dose chest CT (LDCT) showed high sensitivity and ability to quantify lung involvement of COVID-19 pneumopathy. The aim of this study was to describe the prevalence and risk factors for lung involvement in 247 patients with a visual score and assess the prevalence of incidental findin...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670109/ https://www.ncbi.nlm.nih.gov/pubmed/33201409 http://dx.doi.org/10.1186/s13244-020-00939-7 |
_version_ | 1783610673387798528 |
---|---|
author | Castelli, Maxime Maurin, Arnaud Bartoli, Axel Dassa, Michael Marchi, Baptiste Finance, Julie Lagier, Jean-Christophe Million, Matthieu Parola, Philippe Brouqui, Philippe Raoult, Didier Cortaredona, Sebastien Jacquier, Alexis Gaubert, Jean-Yves Habert, Paul |
author_facet | Castelli, Maxime Maurin, Arnaud Bartoli, Axel Dassa, Michael Marchi, Baptiste Finance, Julie Lagier, Jean-Christophe Million, Matthieu Parola, Philippe Brouqui, Philippe Raoult, Didier Cortaredona, Sebastien Jacquier, Alexis Gaubert, Jean-Yves Habert, Paul |
author_sort | Castelli, Maxime |
collection | PubMed |
description | BACKGROUND: Low-dose chest CT (LDCT) showed high sensitivity and ability to quantify lung involvement of COVID-19 pneumopathy. The aim of this study was to describe the prevalence and risk factors for lung involvement in 247 patients with a visual score and assess the prevalence of incidental findings. METHODS: For 12 days in March 2020, 250 patients with RT-PCR positive tests and who underwent LDCT were prospectively included. Clinical and imaging findings were recorded. The extent of lung involvement was quantified using a score ranging from 0 to 40. A logistic regression model was used to explore factors associated with a score ≥ 10. RESULTS: A total of 247 patients were analyzed; 138 (54%) showed lung involvement. The mean score was 4.5 ± 6.5, and the mean score for patients with lung involvement was 8.1 ± 6.8 [1–31]. The mean age was 43 ± 15 years, with 121 males (48%) and 17 asymptomatic patients (7%). Multivariate analysis showed that age > 54 years (odds ratio 4.4[2.0–9.6] p < 0.001) and diabetes (4.7[1.0–22.1] p = 0.049) were risk factors for a score ≥ 10. Multivariate analysis including symptoms showed that only age > 54 years (4.1[1.7–10.0] p = 0.002) was a risk factor for a score ≥ 10. Rhinitis (0.3[0.1–0.7] p = 0.005) and anosmia (0.3[0.1–0.9] p = 0.043) were protective against lung involvement. Incidental imaging findings were found in 19% of patients, with a need for follow-up in 0.6%. CONCLUSION: The prevalence of lung involvement was 54% in a predominantly paucisymptomatic population. Age ≥ 55 years and diabetes were risk factors for significant parenchymal lung involvement. Rhinitis and anosmia were protective against LDCT abnormalities. |
format | Online Article Text |
id | pubmed-7670109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-76701092020-11-18 Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19 Castelli, Maxime Maurin, Arnaud Bartoli, Axel Dassa, Michael Marchi, Baptiste Finance, Julie Lagier, Jean-Christophe Million, Matthieu Parola, Philippe Brouqui, Philippe Raoult, Didier Cortaredona, Sebastien Jacquier, Alexis Gaubert, Jean-Yves Habert, Paul Insights Imaging Original Article BACKGROUND: Low-dose chest CT (LDCT) showed high sensitivity and ability to quantify lung involvement of COVID-19 pneumopathy. The aim of this study was to describe the prevalence and risk factors for lung involvement in 247 patients with a visual score and assess the prevalence of incidental findings. METHODS: For 12 days in March 2020, 250 patients with RT-PCR positive tests and who underwent LDCT were prospectively included. Clinical and imaging findings were recorded. The extent of lung involvement was quantified using a score ranging from 0 to 40. A logistic regression model was used to explore factors associated with a score ≥ 10. RESULTS: A total of 247 patients were analyzed; 138 (54%) showed lung involvement. The mean score was 4.5 ± 6.5, and the mean score for patients with lung involvement was 8.1 ± 6.8 [1–31]. The mean age was 43 ± 15 years, with 121 males (48%) and 17 asymptomatic patients (7%). Multivariate analysis showed that age > 54 years (odds ratio 4.4[2.0–9.6] p < 0.001) and diabetes (4.7[1.0–22.1] p = 0.049) were risk factors for a score ≥ 10. Multivariate analysis including symptoms showed that only age > 54 years (4.1[1.7–10.0] p = 0.002) was a risk factor for a score ≥ 10. Rhinitis (0.3[0.1–0.7] p = 0.005) and anosmia (0.3[0.1–0.9] p = 0.043) were protective against lung involvement. Incidental imaging findings were found in 19% of patients, with a need for follow-up in 0.6%. CONCLUSION: The prevalence of lung involvement was 54% in a predominantly paucisymptomatic population. Age ≥ 55 years and diabetes were risk factors for significant parenchymal lung involvement. Rhinitis and anosmia were protective against LDCT abnormalities. Springer International Publishing 2020-11-17 /pmc/articles/PMC7670109/ /pubmed/33201409 http://dx.doi.org/10.1186/s13244-020-00939-7 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Castelli, Maxime Maurin, Arnaud Bartoli, Axel Dassa, Michael Marchi, Baptiste Finance, Julie Lagier, Jean-Christophe Million, Matthieu Parola, Philippe Brouqui, Philippe Raoult, Didier Cortaredona, Sebastien Jacquier, Alexis Gaubert, Jean-Yves Habert, Paul Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19 |
title | Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19 |
title_full | Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19 |
title_fullStr | Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19 |
title_full_unstemmed | Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19 |
title_short | Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19 |
title_sort | prevalence and risk factors for lung involvement on low-dose chest ct (ldct) in a paucisymptomatic population of 247 patients affected by covid-19 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670109/ https://www.ncbi.nlm.nih.gov/pubmed/33201409 http://dx.doi.org/10.1186/s13244-020-00939-7 |
work_keys_str_mv | AT castellimaxime prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT maurinarnaud prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT bartoliaxel prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT dassamichael prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT marchibaptiste prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT financejulie prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT lagierjeanchristophe prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT millionmatthieu prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT parolaphilippe prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT brouquiphilippe prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT raoultdidier prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT cortaredonasebastien prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT jacquieralexis prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT gaubertjeanyves prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 AT habertpaul prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19 |